Working… Menu

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03599518
Recruitment Status : Completed
First Posted : July 26, 2018
Last Update Posted : July 7, 2020
Information provided by (Responsible Party):
Daiichi Sankyo, Inc. ( Daiichi Sankyo Co., Ltd. )

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 22, 2020
Actual Study Completion Date : June 29, 2020
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 September 14, 2021